Cell Source, Inc. operates as a cell therapy company focused on immunotherapy. Its Veto Cell technology is a next generation immunotherapy technology that enables the selective attenuation of the immune system. The company's Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY.
No Data
No Data
No Data
No Data
No Data
No Data